Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

ClinicalTrials.gov ID: NCT01103323

Public ClinicalTrials.gov record NCT01103323. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Study identification

NCT ID: NCT01103323
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 760 participants

Conditions and interventions

Conditions

Metastatic Colorectal Cancer

Interventions

Regorafenib (Stivarga, BAY73-4506) Drug
Placebo Drug
Best Supportive Care (BSC) Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2010
Primary completion: Jun 30, 2011
Completion: Dec 31, 2013
Last update posted: Jun 23, 2015

2010 – 2014

United States locations

U.S. sites: 26
U.S. states: 17
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Beverly Hills	California	90211	—
Not listed	Los Angeles	California	90033	—
Not listed	Los Angeles	California	90036	—
Not listed	Mission Hills	California	91345	—
Not listed	Orange	California	92868	—
Not listed	Redlands	California	92374	—
Not listed	Santa Maria	California	93454	—
Not listed	Aventura	Florida	33180	—
Not listed	Jacksonville	Florida	32224	—
Not listed	Peoria	Illinois	61615-7828	—
Not listed	Cedar Rapids	Iowa	52403	—
Not listed	New Orleans	Louisiana	70121	—
Not listed	Ann Arbor	Michigan	48106	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Saint Cloud	Minnesota	56303	—
Not listed	Jefferson City	Missouri	65109	—
Not listed	Neptune City	New Jersey	07754	—
Not listed	New York	New York	10011	—
Not listed	Fargo	North Dakota	58122	—
Not listed	Toledo	Ohio	43623	—
Not listed	Scranton	Pennsylvania	18510	—
Not listed	Charleston	South Carolina	29414	—
Not listed	Sumter	South Carolina	29150	—
Not listed	Dallas	Texas	75390-9110	—
Not listed	Salt Lake City	Utah	84106	—
Not listed	Green Bay	Wisconsin	54303	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01103323, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2015 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01103323 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →